Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoGenex Pharmaceuticals, Inc. (noting a discrepancy with the metadata company name "ACHIEVE LIFE SCIENCES, INC.") on March 26, 2009. The report details corporate governance actions taken by the Board of Directors on March 26 and March 27, 2009, specifically regarding the establishment of new compensation policies for directors and executive officers.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of new compensation agreements.
Material Changes Versus Prior Period
- Director Compensation Policy: The Board approved a new policy superseding prior practices.
- Cash: $65,000 annually for the Chair/Lead Director; $44,000 annually for other non-employee directors, paid in quarterly installments.
- Equity: New directors receive an Initial Grant valued at $55,000 (max 20,000 shares) vesting over three years. Annual Grants are valued at $34,000 (max 17,000 shares) vesting over one year. Both grants have a seven-year term.
- Valuation Method: Option value is calculated using the Black-Scholes formula with a four-year expected life, 0% dividend yield, and specific volatility and interest rate inputs.
- Short Term Incentive Program (STIP): The Board adopted a new STIP and related consent forms, superseding prior bonus practices.
- Discretionary Nature: All bonuses for employees, including executive officers, are now discretionary.
- Performance Basis: Executive officer awards are based exclusively on corporate objectives. Actual payments may be less than target amounts depending on results.
- Confidentiality: Specific corporate objectives are withheld from disclosure to prevent competitive harm.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is that executive officer bonus payments are discretionary and contingent upon the attainment of confidential corporate objectives, meaning actual payouts may fall short of established targets.
Investor Verification Checklist
- Verify the correct registrant name (OncoGenex Pharmaceuticals, Inc. vs. metadata listing of Achieve Life Sciences, Inc.).
- Review the filed Exhibits 10.1 and 10.2 for the full text of the Short Term Incentive Awards Program and the Agreement and Consent Form.
- Assess the impact of the new director equity grants on potential dilution, noting the maximum share limits (20,000 for initial, 17,000 for annual).
- Confirm the specific corporate objectives used to determine executive bonuses, noting they are currently confidential.